Literature DB >> 12404306

Citalopram.

Andre F. Joubert1, Connie Sánchez, Frank Larsen.   

Abstract

Citalopram is a selective serotonin (5-HT) reuptake inhibitor (SSRI) developed by H. Lundbeck A/S in Denmark. It is the most selective serotonin antidepressant with proven efficacy, a favourable pharmacokinetic profile and a low potential for interactions with other concomitant medication. The drug has a low incidence of side effects, even when compared to the other SSRIs and good patient compliance and satisfaction is a feature of this drug. These factors make the drug a good choice for depressed patients who require continuation and long-term treatment, as well as for elderly patients. Copyright 2000 John Wiley & Sons, Ltd.

Entities:  

Year:  2000        PMID: 12404306     DOI: 10.1002/1099-1077(200008)15:6<439::AID-HUP222>3.0.CO;2-H

Source DB:  PubMed          Journal:  Hum Psychopharmacol        ISSN: 0885-6222            Impact factor:   1.672


  5 in total

1.  Differential modulation of emotion processing brain regions by noradrenergic and serotonergic antidepressants.

Authors:  Annette Beatrix Brühl; Lutz Jäncke; Uwe Herwig
Journal:  Psychopharmacology (Berl)       Date:  2011-02-26       Impact factor: 4.530

Review 2.  Current Agents in Development for Treating Behavioral and Psychological Symptoms Associated with Dementia.

Authors:  Mehnaz Ahmed; Marlene Malik; Johannes Teselink; Krista L Lanctôt; Nathan Herrmann
Journal:  Drugs Aging       Date:  2019-07       Impact factor: 3.923

3.  Serotonergic and noradrenergic modulation of emotion processing by single dose antidepressants.

Authors:  Annette Beatrix Brühl; Tina Kaffenberger; Uwe Herwig
Journal:  Neuropsychopharmacology       Date:  2010-01       Impact factor: 7.853

4.  A comparison of d, l-fenfluramine and citalopram challenges in healthy adults.

Authors:  Janine D Flory; Stephen B Manuck; James M Perel; Matthew F Muldoon
Journal:  Psychopharmacology (Berl)       Date:  2004-03-02       Impact factor: 4.530

5.  Allelic variation in the serotonin transporter promoter affects neuromodulatory effects of a selective serotonin transporter reuptake inhibitor (SSRI).

Authors:  Peter Eichhammer; Berthold Langguth; Rainer Wiegand; Alexander Kharraz; Ulrich Frick; Göran Hajak
Journal:  Psychopharmacology (Berl)       Date:  2003-02-01       Impact factor: 4.530

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.